Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors

NCT00069277 | Completed Phase 1 Results

• 1 other identifier: E7389-A001-102
• Study Type: interventional
• Target: 21
• Locations: 1 country
• Sites: 3

Brief Summary

The malignancies (advanced solid tumors) that have been chosen for evaluation of E7389 are those where E7389 has demonstrated significant pre-clinical anti-tumor activity, both in vitro and in vivo. The ultimate goal is to demonstrate the clinical activity of E7389 in the treatment of these, and potentially other, tumor types.

Conditions

Cancer

Keywords

Cancer, tumors

Outcome Measures

Primary Outcomes (1)

• Response and Progression Will be Evaluated in This Study Using the New International Criteria Proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee. Changes in Only the Largest Diameter of the Tumor Lesions Are Used.

  12 Weeks

Interventions

E7389 DRUG

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients must have a histologically or cytologically confirmed and measurable advanced solid tumor that has progressed following standard therapy or for which no standard therapy exists (including surgery or radiation therapy)
• Patients may have received prior chemotherapy (limit of two prior chemotherapy regimens)
• Patients must be aged \>= 18 years
• Patients must have a Karnofsky Performance Status of \> 70% -- Patients must have a life expectancy of \> 3 months
• Patients must have adequate renal function as evidenced by serum creatinine \<1.5 mg/dL or creatinine clearance \> 60 mL/minute
• Patients must have adequate bone marrow function as evidenced by absolute neutrophil count \> 1,500/µL and platelets \> 100,000/µL
• Patients must have adequate liver function as evidenced by bilirubin \< 1.5 mg/dL and alanine transaminase (ALAT) and aspartate transaminase (ASAT) \< 2 times the upper limits of normal
• Patients must be willing and able to comply with the study protocol for the duration of the study
• Patients must give written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.

You may not qualify if:

• Patients who have received chemotherapy within three weeks (six weeks if nitrosoureas were received) of E7389 treatment start
• Patients who have not recovered from any chemotherapy related or other therapy related toxicity at study entry
• Patients who require therapeutic doses of anti-coagulant therapy (eg, Coumadin, heparin, low molecular weight heparin). Low doses of anticoagulants used for patency (e.g., lines, catheters, ports) are permitted.
• Women who are pregnant or breastfeeding.
• Women of childbearing potential with either a positive pregnancy test at Screening or no pregnancy test. Women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in the opinion of the Investigator (postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential)
• Fertile men who are not willing to use contraception or fertile men with a female partner who is not willing to use contraception
• Patients who have not successfully completed local therapy for previously treated central nervous system (CNS) metastases and who have not been discontinued from corticosteroids for at least four weeks before starting treatment with E7389. Patients with asymptomatic brain metastases who have no evidence of midline shift on CT scan or MRI may be enrolled without initiation of local therapy for the CNS metastases. In this case, a repeat scan must be performed within four weeks of the original scan to ensure that disease progression is not occurring.
• Patients who have tested positive for HIV
• Patients with severe uncontrolled intercurrent illness/infection (excluding malignancies)
• Patients with cardiovascular impairment
• Patients with organ allografts
• Patients who have received investigational drugs, including immunotherapy, gene therapy, hormone therapy, or other biologic therapy; anti-neoplastic therapy; or radiation therapy (other than required for palliation) within three weeks of E7389 treatment start
• Patients who have had major surgery within four weeks of E7389 treatment start without a full recovery
• Patients with a hypersensitivity to Halichondrin B and/or Halichondrin B-like compounds Patients with other significant disease that, in the Investigator's opinion, would exclude the patient from the study

Sponsors & Collaborators

• Eisai Inc.: lead

Study Sites (3)

Cancer Institute Medical Group

Los Angeles, California, 90025, United States

Location

Premiere Oncology

Santa Monica, California, 90404, United States

Location

Unknown Facility

New Brunswick, New Jersey, 08901, United States

Location

MeSH Terms

Conditions

Neoplasms

Interventions

eribulin

Results Point of Contact

• Title: Eisai Call Center
• Organization: Eisai Inc

888-422-4743

Study Officials

• Dale Schuster, Ph.D

  Eisai Inc.

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: September 19, 2003
• First Posted: September 24, 2003
• Study Start: August 1, 2003
• Primary Completion: April 1, 2005
• Study Completion: April 1, 2005
• Last Updated: April 11, 2012
• Results First Posted: February 9, 2012

Record last verified: 2012-04

Locations

US (3)